Interestingly, the risk of non-fatal stroke was similar between GLP-1 receptor agonists and SGLT2 inhibitors, while only GLP-1 receptor agonists decreased the risk of non-fatal stroke when compared to placebo [77]. The gene discussed is SLC5A2; the disease is stroke disorder.